Immunogenicity and Sustainability of the Immune Response in Brazilian HIV-1-Infected Individuals Vaccinated With Inactivated Triple Influenza Vaccine

被引:2
|
作者
Souza, Thiago Moreno L. [1 ,2 ,3 ]
Santini-Oliveira, Marilia [4 ]
Martorelli, Andressa [1 ,2 ,3 ]
Luz, Paula M. [4 ]
Vasconcellos, Mauricio T. L. [4 ]
Giacoia-Gripp, Carmem B. W. [5 ]
Morgado, Mariza [5 ]
Nunes, Estevao P. [4 ]
Lemos, Alberto S. [4 ]
Ferreira, Ana C. G. [4 ]
Moreira, Ronaldo I. [4 ]
Veloso, Valdilea G. [4 ]
Siqueira, Marilda [1 ]
Grinsztejn, Beatriz [4 ]
Camacho, Luiz A. B. [6 ]
机构
[1] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, NIC WHO, Lab Virus Resp & Sarampo, Rio De Janeiro, Brazil
[2] Fundacao Oswaldo Cruz, Ctr Desenvolvimento Tecnol Saude, Rio De Janeiro, Brazil
[3] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil
[4] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Rio De Janeiro, Brazil
[5] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Rio De Janeiro, Brazil
[6] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil
关键词
influenza; vaccine; HIV; immunogenicity; vaccine mismatch; SEASONAL INFLUENZA;
D O I
10.1002/jmv.24351
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HIV-infected individuals have a higher risk of serious illnesses following infection by infection with influenza. Although anti-influenza vaccination is recommended, immunosuppression may limit their response to active immunization. We followed-up a cohort of HIV-infected individuals vaccinated against influenza to assess the immunogenicity and sustainability of the immune response to vaccination. Individuals were vaccinated 2011 with inactivated triple influenza vaccine (TIV), and they had received in 2010 the monovalent anti-A(H1N1)pdm09 vaccine. The sustainability of the immune response to A (H1N1) pdm09 at 12 months after monovalent vaccination fell, both in individuals given two single or two double doses. For these individuals, A(H1N1) pdm09 component from TIV acted as a booster, raising around 40% the number of seroprotected individuals. Almost 70% of the HIV-infected individuals were already seroprotected to A/H3N2 at baseline. Again, TIV boosted over 90% the seroprotection to A/H3N2. Anti-A/H3N2 titers dropped by 20% at 6 months after vaccination. Pre-vaccination seroprotection rate to influenza B (victoria lineage) was the lowest among those tested, seroconversion rates were higher after vaccination. Seroconversion/protection after TIV vaccination did not differ significantly across categories of clinical and demographic variables. Anti-influenza responses in Brazilian HIV-infected individuals reflected both the previous history of virus circulation in Brazil and vaccination. (C) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:426 / 436
页数:11
相关论文
共 50 条
  • [1] Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients
    Tremblay, Cecile L.
    Rouleau, Danielle
    Fortin, Claude
    Toma, Emil
    Sylla, Mohamed
    Cyr, Lise
    Cote, Serge
    Baz, Mariana
    Sampalis, John
    Trautman, Lydie
    Sekaly, Rafick-Pierre
    Boivin, Guy
    VACCINE, 2011, 29 (07) : 1359 - 1363
  • [2] Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients
    de Verdiere, Nathalie Colin
    Durier, Christine
    Samri, Assia
    Meiffredy, Vincent
    Launay, Odile
    Matheron, Sophie
    Mercier-Delarue, Severine
    Even, Sophie
    Aboulker, Jean-Pierre
    Molina, Jean-Michel
    Autran, Brigitte
    Simon, Francois
    AIDS, 2018, 32 (16) : 2291 - 2299
  • [3] Identification of immunodominant epitopes in inactivated tat-vaccinated healthy and HIV-1-infected volunteers
    Noonan, DM
    Gringeri, A
    Meazza, TR
    Rosso, O
    Mazza, S
    Muça-Perja, M
    Le Buanec, H
    Accolla, RS
    Albini, A
    Ferrini, S
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (01) : 47 - 55
  • [4] Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults
    Hatakeyama, Shuji
    Iwatsuki-Horimoto, Kiyoko
    Okamoto, Koh
    Nukui, Yoko
    Yata, Nahoko
    Fujita, Akira
    Inaba, Shigeki
    Yotsuyanagi, Hiroshi
    Kawaoka, Yoshihiro
    VACCINE, 2011, 29 (49) : 9224 - 9228
  • [5] Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore
    Lau, Yuk-Fai
    Tang, Lay-Hoon
    Lye, David Chien
    Ooi, Eng-Eong
    Leo, Yee-Sin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (03) : 551 - 560
  • [6] Immune Response after a Single Dose of the 2010/11 Trivalent, Seasonal Influenza Vaccine in HIV-1-Infected Patients and Healthy Controls
    Bickel, Markus
    Lassmann, Christin
    Wieters, Imke
    Doerr, Hans Wilhelm
    Herrmann, Eva
    Wicker, Sabine
    Brodt, Hans Reinhard
    Stephan, Christoph
    Allwinn, Regina
    Jung, Oliver
    HIV CLINICAL TRIALS, 2013, 14 (04): : 175 - 181
  • [7] Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients
    Yamanaka, H
    Teruya, K
    Tanaka, M
    Kikuchi, Y
    Takahashi, T
    Kimura, S
    Oka, S
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (02) : 167 - 173
  • [8] Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women
    Kojic, Erna Milunka
    Kang, Minhee
    Cespedes, Michelle S.
    Umbleja, Triin
    Godfrey, Catherine
    Allen, Reena T.
    Firnhaber, Cynthia
    Grinsztejn, Beatriz
    Palefsky, Joel M.
    Webster-Cyriaque, Jennifer Y.
    Saah, Alfred
    Aberg, Judith A.
    Cu-Uvin, Susan
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (01) : 127 - 135
  • [9] Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status
    Mugo, Nelly R.
    Eckert, Linda
    Magaret, Amanlia S.
    Cheng, Anqi
    Mwaniki, Lawrence
    Ngure, Kenneth
    Celum, Connie
    Baeten, Jared M.
    Galloway, Denise A.
    Wamalwa, Dalton
    Wald, Anna
    VACCINE, 2018, 36 (46) : 7025 - 7032
  • [10] Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine vs. standard-dose intramuscular vaccine in HIV-1-infected adults
    Ansaldi, Filippo
    Valle, Laura
    de Florentiis, Daniela
    Parodi, Valentina
    Murdaca, Giuseppe
    Bruzzone, Bianca M.
    Durando, Paolo
    Setti, Maurizio
    Icardi, Giancarlo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (08) : 1048 - 1052